Similar articles

• [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].

  Matsushima A, Enomoto M, Yokoo Y, Arai M, Kobayashi T, Okuno F, Hirano Y, Sujita K, Eto S, Takagi T, et al. Matsushima A, et al. Rinsho Byori. 1989 Jun;37(6):683-6. Rinsho Byori. 1989. PMID: 2477568 Japanese. No abstract available.
• [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].

  Arima K, Kodama T, Suga M, Sakamoto H, Ohe Y, Yachi A. Arima K, et al. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):3049-52. Gan To Kagaku Ryoho. 1989. PMID: 2476968 Japanese.
• [PIVKA-II high-sensitivity PIVKA-II].

  Fujiyama S. Fujiyama S. Nihon Rinsho. 2001 Oct;59 Suppl 6:349-55. Nihon Rinsho. 2001. PMID: 11761970 Review. Japanese. No abstract available.
• Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.

  Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M. Tanaka Y, et al. Hepatogastroenterology. 1999 Jul-Aug;46(28):2464-8. Hepatogastroenterology. 1999. PMID: 10522021
• [Tumor markers for hepatocellular carcinoma].

  Tateishi R, Enooku K, Shiina S, Koike K. Tateishi R, et al. Nihon Rinsho. 2012 May;70(5):821-7. Nihon Rinsho. 2012. PMID: 22620007 Review. Japanese.